A Multicenter, Single-Arm, Open-Label Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Otherwise Healthy Pediatric Patients From Birth to < 1 Year With Influenza-Like Symptoms
Phase of Trial: Phase III
Latest Information Update: 07 Dec 2019
Price : $35 *
At a glance
- Drugs Baloxavir-marboxil (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Registrational
- Acronyms MINISTONE-1
- Sponsors Roche
- 01 Mar 2019 Planned End Date changed from 23 May 2020 to 2 Sep 2020.
- 01 Mar 2019 Planned primary completion date changed from 23 May 2020 to 2 Sep 2020.
- 28 Nov 2018 Status changed from not yet recruiting to recruiting.